Allogenetics

Allogenetics’ mission is to enable longer and healthier lives for transplant patients by fine-tuning the balance between host immune tolerance and protection. We are advancing an ex vivo gene therapy designed as a one-time treatment to modify the donor organ. Our goal is to eliminate the need for lifelong immunosuppression and its challenges to improve graft survival and patient quality of life.

The company’s proprietary technology platform enables a calibrated knockdown of cell-surface antigen presentation (MHC class I and II) to evade graft rejection while retaining full immune competence. Building on compelling proof-of-concept in animal models, we will bring our novel organ-agnostic approach into human clinical trials, starting with lung grafts. By leveraging our immune-tolerance approach we are building a new path toward addressing life-threatening conditions and the global organ shortage crisis.